Home / Products / Genome-edited Cells / NBR1 Knockout KYSE-150 Cell Line

NBR1 Knockout KYSE-150 Cell Line

Cat. No. ARG43991
Product Type:

In Stock Cell Lines

Species:

Homo sapiens (Human)

Tissue Source:

Esophagus

Growth Properties:

Adherent

In stock
Request a Quote

Short Description 🔒

The NBR1 Knockout KYSE-150 Cell Line is a CRISPR/Cas9-edited human esophageal squamous cell carcinoma model with targeted disruption of the autophagy receptor NBR1. NBR1 mediates selective degradation of ubiquitinated substrates through interactions with p62/SQSTM1, LC3/GABARAP proteins, and ATG8 family members, playing critical roles in aggrephagy and pexophagy. This engineered cell line enables dissection of autophagy-related pathways in cancer biology, particularly for studying protein aggregate clearance, mTOR signaling, and drug resistance mechanisms. It is suitable for autophagic flux assays, co-immunoprecipitation, immunofluorescence, and proliferation analyses. Contact Ascent Research for more information.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Esophagus
Disease:
Squamous cell carcinoma
Morphology:
Epithelial-like
Growth Mode:
Adherent
Age:
49 years
Sex of Donor:
Female
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
KYSE-150
Gene Name:
NBR1
Gene Identifier:
NCBI Gene ID 4077

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The NBR1 Knockout KYSE-150 Cell Line is a genetically engineered human cell model featuring CRISPR/Cas9-mediated disruption of the NBR1 gene. This knockout cell line provides a targeted loss-of-function platform for dissecting the roles of NBR1 in selective autophagy processes. By eliminating endogenous NBR1 expression, the model enables precise investigation of cargo recognition, aggregate clearance, and related signaling cascades in a controlled in vitro system. The product is delivered as a ready-to-use cell line suitable for functional assays in cancer biology and autophagy research.

The parental KYSE-150 cell line is a well-established human esophageal squamous cell carcinoma (ESCC) model derived from an epithelial origin. KYSE-150 cells exhibit characteristic features of esophageal cancer, including dysregulated growth signaling and invasive properties, making them a relevant host for studying oncogenic mechanisms and therapeutic vulnerabilities. This epithelial cell background provides a physiologically pertinent context for examining the interplay between autophagy and cancer progression, particularly in esophageal malignancies.

NBR1 functions as a pivotal autophagy cargo receptor, mediating the selective degradation of ubiquitinated substrates. It interacts with ubiquitinated protein aggregates and damaged organelles via its UBA domain, while its LIR motif engages autophagosomal LC3/GABARAP proteins to direct cargo for lysosomal destruction. NBR1 cooperates with p62/SQSTM1 and ATG8 family members, integrating signals from upstream regulators such as TFEB and mTORC1. Downstream, it targets ubiquitinated protein aggregates and peroxisomes, linking it to aggrephagy, pexophagy, and mTOR signaling pathway modulation. The protein also interacts with TAX1BP1, further expanding its network in cargo sorting and clearance.

In esophageal squamous cell carcinoma, NBR1-mediated autophagy is implicated in tumor cell homeostasis, stress adaptation, and resistance to therapeutic agents. Loss of NBR1 in the KYSE-150 background allows dissection of its contribution to oncogenic processes, including proliferation, migration, and drug sensitivity. Given the role of autophagy in cancer cell survival under nutrient deprivation and hypoxic conditions, this knockout model is valuable for probing the molecular determinants of resilience in esophageal cancer cells.

Representative research applications include monitoring autophagic flux with bafilomycin A1 treatment, evaluating LC3 puncta formation by immunofluorescence, assessing NBR1-LC3 interactions via co-immunoprecipitation, and quantifying cell proliferation through MTT or CCK-8 assays. The model also supports wound healing migration assays and drug sensitivity profiling to explore chemoresistance mechanisms. Collectively, these tools empower investigations into autophagy-dependent cancer pathways. For further details and batch-specific data, please contact Ascent Research.